Takhzyro

Takhzyro

lanadelumab

Manufacturer:

Takeda

Distributor:

Zuellig Pharma

Marketer:

Takeda
Concise Prescribing Info
Contents
Lanadelumab
Indications/Uses
Routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients ≥12 yr.
Dosage/Direction for Use
SC Recommended starting dose: 300 mg every 2 wk. Patients who are stably attack free on treatment, especially in patients w/ low wt May reduce dose every 4 wk. Recommended inj site: Abdomen, thighs, & upper outer arms.
Contraindications
Special Precautions
Discontinue immediately in case of severe hypersensitivity reaction. Not intended for acute HAE attacks. Initiate individualized treatment w/ an approved rescue medication in case of breakthrough HAE attack. Interference w/ coagulation test. May affect ability to drive & use machines. Avoid use during pregnancy. Lactation. Childn <12 yr.
Adverse Reactions
Inj site reactions eg, pain, erythema, bruising, discomfort, haematoma, haemorrhage, pruritus, swelling, induration, paraesthesia, reaction, warmth, oedema & rash. Hypersensitivity eg, pruritus, discomfort & tingling of tongue; dizziness; maculopapular rash; myalgia; increased ALT & AST.
Drug Interactions
Additive effect w/ rescue medication C1 esterase inhibitor.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
B06AC05 - lanadelumab ; Belong to the class of drugs used in the treatment of hereditary angioedema.
Presentation/Packing
Form
Takhzyro soln for inj 300 mg/2 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in